多西他赛联合奥沙利铂化疗对晚期非小细胞肺癌的临床疗效

Clinical study of docetaxel combined with oxaliplatin in advanced non-small cell lung cancer

目的探讨多西他赛联合奥沙利铂治疗晚期非小细胞肺癌化疗的临床疗效。方法选取住院治疗的118例晚期非小细胞肺癌患者,采用随机数字法分为观察组和对照组各59例,对照组患者行顺铂联合多西他赛治疗,观察组患者行奥沙利铂联合多西他赛治疗,比较两组患者实体肿瘤疗效差异、疾病无进展生存时间、总体生存时间以及不良反应发生率等疗效指标差异。结果观察组患者完全缓解、部分缓解以及临床有效率依次为11.9%(7/59)、47.5%(28/59)、59.3%(35/59),对照组为8.5%(5/59)、39.0%(23/59)、47.5%(28/59),差异无统计学意义(P>0.05)。观察组患者疾病无进展生存时间、总体生存时间依次(12.17±0.98)月、(20.07±2.38)月,均明显长于对照组的(8.48±0.68)月、(16.07±2.78)月(P<0.05),观察组患者骨髓抑制、消化道异常、白细胞下降、外周神经毒性、肝功能异常等不良反应发生率均明显低于对照组,且程度明显轻于对照组,差异均具有统计学意义(P<0.05)。结论多西他赛联合奥沙利铂治疗晚期非小细胞肺癌化疗的临床疗效明确,不良反应发生率较低,是治疗晚期非小细胞肺癌的有效措施之一。

Objective To investigate the clinical effect of docetaxel combined with oxaliplatin in advanced nonsmall cell lung cancer.Methods A total of 118 patients with advanced non-small-cell lung cancer were randomly divided into observation group and control group,59 cases in each group.The control group was treated with cisplatin combined with docetaxel and the observation group was treated with oxaliplatin combined with docetaxel.The differences of solid tumor efficacy,time to progression,overall survival time,and adverse reaction rate of patients in both groups were compared.Results The rates of complete remission,partial remission and clinical effect in observation group were 11.9%（7/59）,47.5%（28/59）and 59.3%（35/59）,respectively,which were higher than8.5%（5/59）,39.0%（23/59）and 47.5%（28/59）in control group,respectively（P 0.05）.The time to progression and overall survival time in observation group were（12.17±0.98）months and（20.07±2.38）months,respectively,which were significantly higher than（8.48±0.68）months and（16.07±2.78）months in control group,respectively（P 0.05）.The rates of bone marrow depression,digestive tract abnormalities,decreased white blood cells,peripheral nerve toxicity,liver function abnormalities and other adverse reactions were significantly lower in observation group than in control group,and the degree was significantly improved in control group（P 0.05）.Conclusion Docetaxel combined with oxaliplatin has an affirmative clinical efficacy in advanced non-small cell lung cancer with lower adverse reactions and is one of the effective measures in the treatment of advanced non-small cell lung cancer.